Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Evaluating the market potential of the Viaskin Milk patch in treating patients with cow’s milk protein allergy (CMPA)

Ticker(s): DBVT, AIMT

Who's the expert?

Name: Dr Melanie Makhija - MD

Institution: Northwestern

  • Assistant Professor, Pediatrics at Northwestern; Clinical and research interests focus on food allergy including oral, sublingual and epicutaneous immunotherapy for food, eosinophilic esophagitis, asthma, and primary immunodeficiency.
  • Treats approximately 500 patients with peanut allergy & 200 patients with cow’s milk allergy (CMPA).
  • Primary and co-investigator on several multi-center national and international food allergy, immunology and asthma clinical trials.

Interview Questions

Please describe your clinical practice; roughly how many patients with cow’s milk protein allergy (CMPA) do you currently treat?

Added By: userbfe6b45e

What is your current treatment for patients with milk allergy?

Added By: userbfe6b45e

What are your thoughts on the initial data from MILES trial (Viaskin MILk Efficacy and Safety) for Viaskin Milk?

Added By: userbfe6b45e

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.